85 related articles for article (PubMed ID: 17360185)
21. Prognostic utility of fluorescence in situ hybridization for determining HER2 gene amplification in breast cancer.
Kammori M; Kurabayashi R; Kashio M; Sakamoto A; Yoshimoto M; Amano S; Kaminishi M; Yamada T; Takubo K
Oncol Rep; 2008 Mar; 19(3):651-6. PubMed ID: 18288397
[TBL] [Abstract][Full Text] [Related]
22. Are risk factors for breast cancer similar in women with inflammatory breast cancer and in those with non-inflammatory breast cancer?
Lê MG; Arriagada R; Bahi J; Pfeiffer F; Cammoun M; Tabbane F; Rubino C
Breast; 2006 Jun; 15(3):355-62. PubMed ID: 16198566
[TBL] [Abstract][Full Text] [Related]
23. [Pure colloid carcinoma of the breast: anatomoclinical study of seven cases].
Chtourou I; Makni SK; Bahri I; Abbes K; Sellami A; Fakhfakh I; Gouiaa N; Ayadi L; Frikha M; Daoud J; Boudawara TS
Cancer Radiother; 2009 Jan; 13(1):37-41. PubMed ID: 18703371
[TBL] [Abstract][Full Text] [Related]
24. Basal-HER2 phenotype shows poorer survival than basal-like phenotype in hormone receptor-negative invasive breast cancers.
Liu H; Fan Q; Zhang Z; Li X; Yu H; Meng F
Hum Pathol; 2008 Feb; 39(2):167-74. PubMed ID: 18045647
[TBL] [Abstract][Full Text] [Related]
25. Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy.
Johnston S; Trudeau M; Kaufman B; Boussen H; Blackwell K; LoRusso P; Lombardi DP; Ben Ahmed S; Citrin DL; DeSilvio ML; Harris J; Westlund RE; Salazar V; Zaks TZ; Spector NL
J Clin Oncol; 2008 Mar; 26(7):1066-72. PubMed ID: 18212337
[TBL] [Abstract][Full Text] [Related]
26. Triple-negative breast carcinoma in women from Vietnam and the United States: characterization of differential marker expression by tissue microarray.
Williams DJ; Cohen C; To TV; Page AJ; Lawson D; Sussman ZM; Nassar A
Hum Pathol; 2009 Aug; 40(8):1176-81. PubMed ID: 19368951
[TBL] [Abstract][Full Text] [Related]
27. Incomplete surgical resection of ductal carcinomas in situ results in activation of ERBB2 in residual breast cancer cells.
Singer CF; Hudelist G; Fuchs EM; Köstler W; Fink-Retter A; Gschwantler-Kaulich D; Gnant M; Lamm W; Rudas M; Czerwenka K; Kubista E
Endocr Relat Cancer; 2009 Mar; 16(1):73-83. PubMed ID: 18948375
[TBL] [Abstract][Full Text] [Related]
28. Relapse-free survival in breast cancer patients is associated with a gene expression signature characteristic for inflammatory breast cancer.
Van Laere S; Beissbarth T; Van der Auwera I; Van den Eynden G; Trinh XB; Elst H; Van Hummelen P; van Dam P; Van Marck E; Vermeulen P; Dirix L
Clin Cancer Res; 2008 Nov; 14(22):7452-60. PubMed ID: 19010862
[TBL] [Abstract][Full Text] [Related]
29. Short-term outcome of primary operated early breast cancer by hormone and HER-2 receptors.
Brouckaert O; Pintens S; Van Belle V; Van Huffel S; Camerlynck E; Amant F; Leunen K; Smeets A; Berteloot P; Van Limbergen E; Decock J; Hendrickx W; Weltens C; Van den Bogaert W; Vanden Bempt I; Drijkoningen M; Paridaens R; Wildiers H; Vergote I; Christiaens MR; Neven P
Breast Cancer Res Treat; 2009 May; 115(2):349-58. PubMed ID: 18629635
[TBL] [Abstract][Full Text] [Related]
30. Pattern of metastatic spread in triple-negative breast cancer.
Dent R; Hanna WM; Trudeau M; Rawlinson E; Sun P; Narod SA
Breast Cancer Res Treat; 2009 May; 115(2):423-8. PubMed ID: 18543098
[TBL] [Abstract][Full Text] [Related]
31. Comparison of inflammatory breast cancer and noninflammatory breast cancer in Western Turkey.
Saydam BK; Goksel G; Korkmaz E; Zekioglu O; Kapkac M; Sanli UA; Uslu R; Sezgin C
Med Princ Pract; 2008; 17(6):475-80. PubMed ID: 18836277
[TBL] [Abstract][Full Text] [Related]
32. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
[TBL] [Abstract][Full Text] [Related]
33. [High-throughput quantification of tissue microarrays: identification of candidate target proteins in inflammatory breast cancer].
Taranger-Charpin C; Andrac-Meyer L; Dales JP; Carpentier-Meunier S; Andonian C; Lavaut MN; Allasia C; Bonnier P
Bull Acad Natl Med; 2007 Feb; 191(2):361-74; discussion 374-6. PubMed ID: 17969554
[TBL] [Abstract][Full Text] [Related]
34. Validation of a tissue microarray to study differential protein expression in inflammatory and non-inflammatory breast cancer.
Van den Eynden GG; Van der Auwera I; Van Laere S; Colpaert CG; van Dam P; Merajver S; Kleer CG; Harris AL; Van Marck EA; Dirix LY; Vermeulen PB
Breast Cancer Res Treat; 2004 May; 85(1):13-22. PubMed ID: 15039594
[TBL] [Abstract][Full Text] [Related]
35. Loss of Plexin B1 is highly prognostic in low proliferating ER positive breast cancers--results of a large scale microarray analysis.
Rody A; Karn T; Ruckhäberle E; Hanker L; Metzler D; Müller V; Solbach C; Ahr A; Gätje R; Holtrich U; Kaufmann M
Eur J Cancer; 2009 Feb; 45(3):405-13. PubMed ID: 19054665
[TBL] [Abstract][Full Text] [Related]
36. c-Met overexpression in inflammatory breast carcinomas: automated quantification on tissue microarrays.
Garcia S; Dalès JP; Jacquemier J; Charafe-Jauffret E; Birnbaum D; Andrac-Meyer L; Lavaut MN; Allasia C; Carpentier-Meunier S; Bonnier P; Charpin-Taranger C
Br J Cancer; 2007 Jan; 96(2):329-35. PubMed ID: 17242702
[TBL] [Abstract][Full Text] [Related]
37. Clinical and pathological response to primary chemotherapy in patients with locally advanced breast cancer grouped according to hormonal receptors, Her2 status, grading and Ki-67 proliferation index.
Miglietta L; Vanella P; Canobbio L; Parodi MA; Guglielmini P; Boccardo F
Anticancer Res; 2009 May; 29(5):1621-5. PubMed ID: 19443376
[TBL] [Abstract][Full Text] [Related]
38. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer.
Baselga J; Semiglazov V; van Dam P; Manikhas A; Bellet M; Mayordomo J; Campone M; Kubista E; Greil R; Bianchi G; Steinseifer J; Molloy B; Tokaji E; Gardner H; Phillips P; Stumm M; Lane HA; Dixon JM; Jonat W; Rugo HS
J Clin Oncol; 2009 Jun; 27(16):2630-7. PubMed ID: 19380449
[TBL] [Abstract][Full Text] [Related]
39. The sensitivity and specificity of estrogen receptor, progesterone receptor and HER-2 staining in core biopsies of invasive breast carcinomas.
Frederik P; Cecile C; Tjalma WA
Breast J; 2007; 13(4):436-7. PubMed ID: 17593058
[No Abstract] [Full Text] [Related]
40. Expression and prognostic significance of metalloproteases and their inhibitors in luminal A and basal-like phenotypes of breast carcinoma.
González LO; Corte MD; Junquera S; González-Fernández R; del Casar JM; García C; Andicoechea A; Vázquez J; Pérez-Fernández R; Vizoso FJ
Hum Pathol; 2009 Sep; 40(9):1224-33. PubMed ID: 19439346
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
